NCT05324501View on ClinicalTrials.gov

A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma

PHASE1TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

October 19, 2022

Primary Completion Date

September 10, 2024

Study Completion Date

September 10, 2024

Conditions
Recurrent Glioblastoma
Interventions
DRUG

MTX110

Soluble panobinostat

DEVICE

Programmable pump and catheter system

To allow Convection-Enhanced Delivery (CED)

Trial Locations (2)

27710

Duke University Hospital, Durham

32207

Baptist MD Anderson, Jacksonville

Sponsors
All Listed Sponsors
lead

Biodexa Pharmaceuticals

INDUSTRY